Keywords: abbott, depakote, overtakes, lithium, mania, laboratories, divalproex
Abbott's Depakote Overtakes Lithium For Mania
Article | 04 June 1998
Abbott Laboratories' Depakote (divalproex sodium) has overtakenlithium as the most-prescribed agent in the USA for the treatment of manic episodes ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
